Join our daily newsletter At The Bell to receive exclusive market insights
- Incannex Healthcare (IHL) is looking to secure an international patent for the use of tetrahydrocannabinol (THC) in obstructive sleep apnoea treatment
- Should it be granted, the patent would allow IHL to protect its IHL-42X sleep apnoea treatment on an international scale
- The news comes in conjunction with being granted ethics approval to expand its clinical trials in this area on benefited patients for an extended timeframe
- Incannex Healthcare shares are up 1.82 per cent and trading at 28 cents at 11:26 am AEST
Incannex Healthcare (IHL) is looking to secure an international patent for the use of tetrahydrocannabinol (THC) in obstructive sleep apnoea treatment.
The company filed for international patent — entitled “Methods for the treatment of obstructive sleep apnoea” — as part of its IHL-42X clinical development programme.
Specifically, the patent makes the claim that the IHL-42X formulation of acetazolamide — a registered off-patent pharmaceutical — combined with THC, could be a treatment method for obstructive sleep apnoea.
The application was filed pursuant to the Patent Cooperation Treaty, which IHL said allows it to pursue patent protection internationally, including key North American, the European Union, Japanese and Australian markets.
Data from IHL trials that support this claim are also included in the patent while trials at the University of Western Australia Centre for Sleep Science remain ongoing.
Final results of the trial are expected towards the end of 2021 once all subjects have completed treatment and the Clinical Study Report is finalised.
In other news, Incannex was also granted ethics approval to an open-label
extension to its phase 2b clinical trial, which will recruit people who have experienced a benefit from the sleep apnoea treatment and will assess its performance over an extended timeframe.
Incannex Healthcare Chief Executive Officer and Managing Director Joel Latham said the company was delighted to receive ethics approval.
“Patients who have finished their dosing regimens in the phase 2b trial are now eligible to use IHL-42X every day for an extended period and the data we gather from this program will be invaluable to our ongoing FDA development plan,” he said.
Incannex Healthcare shares were up 1.82 per cent and trading at 28 cents at 11:26 am AEST.
